Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)

Group 1 - Novavax granted non-qualified stock options and restricted stock units to Ruxandra Draghia-Akli as an inducement for her employment, effective November 11, 2024 [1][2] - The non-qualified stock option allows the purchase of 64,150 shares at an exercise price of $9.01, with a ten-year term and a vesting schedule based on continued employment [2] - The restricted stock units consist of 42,770 shares, vesting one-third on each of the first three anniversaries of the grant date, also contingent on continued employment [2] Group 2 - Novavax is a global company focused on developing innovative vaccines, including a COVID-19 vaccine and candidates for COVID-19-Influenza Combination and stand-alone influenza vaccines [3] - The company utilizes a recombinant protein approach and patented Matrix-M adjuvant to enhance immune response [3] - Novavax's adjuvant is also part of the malaria vaccine developed by the University of Oxford and Serum Institute of India [3]